Top

Published in:

01-06-2018 | PHASE I STUDIES

Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results

A phase I clinical trial

Authors: Dana B. Cardin, Laura W. Goff, Emily Chan, Jennifer G. Whisenant, G. Dan Ayers, Naoko Takebe, Lori R. Arlinghaus, Thomas E. Yankeelov, Jordan Berlin, Nipun Merchant

Published in: Investigational New Drugs | Issue 3/2018

Summary

Pancreatic adenocarcinoma remains a major therapeutic challenge, as the poor (<8%) 5-year survival rate has not improved over the last three decades. Our previous preclinical data showed cooperative attenuation of pancreatic tumor growth when dasatinib (Src inhibitor) was added to erlotinib (EGFR inhibitor) and gemcitabine. Thus, this study was designed to determine the maximum-tolerated dose of the triplet combination. Standard 3 + 3 dose escalation was used, starting with daily oral doses of 70 mg dasatinib and 100 mg erlotinib with gemcitabine on days 1, 8, and 15 (800 mg/m²) of a 28-day cycle (L₀). Nineteen patients were enrolled, yet 18 evaluable for dose-limiting toxicities (DLTs). One DLT observed at L₀, however dasatinib was reduced to 50 mg (L₋₁) given side effects observed in the first two patients. At L₋₁, a DLT occurred in 1/6 patients and dose was re-escalated to L₀, where zero DLTs reported in next four patients. Dasatinib was escalated to 100 mg (L₁) where 1/6 patients experienced a DLT. Although L₁ was tolerable, dose escalation was stopped as investigators felt L₁ was within the optimal therapeutic window. Most frequent toxicities were anemia (89%), elevated aspartate aminotransferase (79%), fatigue (79%), nausea (79%), elevated alanine aminotransferase (74%), lymphopenia (74%), leukopenia (74%), neutropenia (63%), and thrombocytopenia (63%), most Grade 1/2. Stable disease as best response was observed in 69% (9/13). Median progression-free and overall survival was 3.6 and 8 months, respectively. Dasatinib, erlotinib, and gemcitabine was safe with manageable side effects, and with encouraging preliminary clinical activity in advanced pancreatic cancer.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 CrossRefPubMed

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of U, Intergroup P (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825. https://doi.org/10.1056/NEJMoa1011923 CrossRefPubMed

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369 CrossRef

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials G (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 25(15):1960–1966. https://doi.org/10.1200/JCO.2006.07.9525 CrossRefPubMed

Roskoski R, Jr. (2015) Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res 94:9–25. doi:https://doi.org/10.1016/j.phrs.2015.01.003

Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (2002) Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94(2):344–351. https://doi.org/10.1002/cncr.10221 CrossRefPubMed

Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP (2008) Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 27(49):6365–6375. https://doi.org/10.1038/onc.2008.250 CrossRefPubMedPubMedCentral

Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, Barge A, Green T, Fennell M, Bruns CJ (2004) Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10(23):8028–8036. https://doi.org/10.1158/1078-0432.CCR-04-0621 CrossRefPubMed

Serrels B, Serrels A, Mason SM, Baldeschi C, Ashton GH, Canel M, Mackintosh LJ, Doyle B, Green TP, Frame MC, Sansom OJ, Brunton VG (2009) A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. Carcinogenesis 30(2):249–257. https://doi.org/10.1093/carcin/bgn278 CrossRefPubMed

10.

Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB (2010) Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 9(8):2322–2332. https://doi.org/10.1158/1535-7163.MCT-09-1212 CrossRefPubMedPubMedCentral

11.

Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE (2006) Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 168(3):962–972. https://doi.org/10.2353/ajpath.2006.050570 CrossRefPubMedPubMedCentral

12.

Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP, Jimeno A, Messersmith WA, Hidalgo M (2009) Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 15(12):4138–4146. https://doi.org/10.1158/1078-0432.CCR-08-3021 CrossRefPubMed

13.

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801–1806. https://doi.org/10.1126/science.1164368 CrossRefPubMedPubMedCentral

14.

Nagaraj NS, Washington MK, Merchant NB (2011) Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 17(3):483–493. https://doi.org/10.1158/1078-0432.CCR-10-1670 CrossRefPubMedPubMedCentral

15.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

16.

Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G (2010) Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28(8):1387–1394. https://doi.org/10.1200/JCO.2009.25.4029 CrossRefPubMedPubMedCentral

17.

Uronis HE, Bullock K, Blobe G, Hsu S, Morse M, Nixon A, Haley S, O’Neill M, Hurwitz H, Bendell J (2009) A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors. J Clin Oncol 27(15_suppl):e15506–e15506. https://doi.org/10.1200/jco.2009.27.15_suppl.e15506

18.

Gore JC, Xu J, Colvin DC, Yankeelov TE, Parsons EC, Does MD (2010) Characterization of tissue structure at varying length scales using temporal diffusion spectroscopy. NMR Biomed 23(7):745–756. https://doi.org/10.1002/nbm.1531 CrossRefPubMedPubMedCentral

19.

Anderson AW, Xie J, Pizzonia J, Bronen RA, Spencer DD, Gore JC (2000) Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging 18(6):689–695CrossRefPubMed

20.

Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ (1999) Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1(2):113–117CrossRefPubMedPubMedCentral

21.

Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD (2014) A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol 7(5):644–649. https://doi.org/10.1016/j.tranon.2014.07.005 CrossRefPubMedPubMedCentral

22.

Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE (2015) Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. Investig Radiol 50(4):195–204. https://doi.org/10.1097/RLI.0000000000000100 CrossRef

23.

Cui Y, Zhang XP, Sun YS, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248(3):894–900. https://doi.org/10.1148/radiol.2483071407 CrossRefPubMed

Title: Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results
A phase I clinical trial
Authors: Dana B. Cardin
Laura W. Goff
Emily Chan
Jennifer G. Whisenant
G. Dan Ayers
Naoko Takebe
Lori R. Arlinghaus
Thomas E. Yankeelov
Jordan Berlin
Nipun Merchant
Publication date: 01-06-2018
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2018
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-017-0519-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases

Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report

Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report

Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin

LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice

Cyclodextrin polymers as nanocarriers for sorafenib

Keynote webinar | Spotlight on antibody–drug conjugates in cancer